"Alpha- Antitrypsin Deficiency (AATD) - Epidemiology Forecast to 2027" report provides a comprehensive analysis of the disease epidemiology in the 7MM (United States, Germany, France, Italy, Spain, UK and Japan). The study period of the report is 2017-2027. This report provides understanding of the patients affected, diagnostic patterns, treatment trends and unmet medical needs.

The overview part of the report helps to develop a deep insights regarding AATD, its symptoms, pathophysiology and treatment approaches. The epidemiology section gives the detail about the total patient pool of AATD. It also includes the explanation of changing trends of epidemiology by exploring numerous studies and views of key opinion leaders.
The disease epidemiology covered in the report is segmented into two parts: Population at the risk of developing AATD on the basis of allele [PiSS, PiSZ, PiZZ) and Prevalent cases of AATD in 6 Major Markets (United States and EU5 (Germany, Spain, Italy, France and United Kingdom). Population at risk of Alpha-1-Antitrypsin Deficiency has been calculated on the basis of direct epidemiological approach that uses findings of genetic epidemiological surveys. As AATD is quite rare in Japan, the report features the diagnosed population of AATD in Japan.

Report Scope
• The report covers detailed overview of Alpha- Antitrypsin Deficiency (AATD) explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns
• The report provides the insight about the historical and forecasted patient pool of Alpha- Antitrypsin Deficiency (AATD) in 7 major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan
• The Report assesses the disease risk and burden and highlights the unmet needs of the disease
• The Report helps to recognize the growth opportunities in the 7MM with respect to the patient population
• The report provides the population at risk of developing AATD and prevalence of AATD in 6MM and diagnosed population of AATD in Japan

Key strengths
• 10 Year Forecast of Alpha- Antitrypsin Deficiency (AATD) epidemiology
• 7MM Coverage
• Total Prevalent Cases of Alpha- Antitrypsin Deficiency (AATD)
• Prevalent population of AATD and population at risk of developing AATD

Key assessments
• Patient Segmentation
• Disease Risk & Burden
• Risk of disease by the segmentation
• Factors driving growth in a specific patient population